Regeneron Pharmaceuticals, Inc.
corporate_fare Company Profile
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 40 items for REGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-01, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for REGN spans 8-K, 13F-HR, 10-Q.
Recent high-impact activity:
- Regeneron's Ovarian Cancer Drug Shows 73% Response Rate but High Toxicity, Shares Slide
- Trevogrumab Preserves 70% of Muscle Lost During GLP-1 Weight Loss in Phase 2
- Regeneron and Sanofi Expand Alliance with $1B Upfront for Next-Gen Immunology Antibodies
- Regeneron Drug Plus Novo's Semaglutide Cuts Muscle Loss in New Data
- Regeneron Replaces Annual Equity with One-Time 10-Year Performance Awards for CEO and CSO
Financial Snapshot
Short Interest & Short Volume
4.42 days to coverFINRA reported short interest of 2,526,446 shares in REGN as of the September 15, 2026 settlement, a 1.0% decrease from the prior period — about 4.4 days to cover at its recent average daily volume. On October 2, 2026, 52.0% of REGN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.